Literature DB >> 17766320

Drug-induced QT prolongation and proarrhythmia: an inevitable link?

Kamran Ahmad1, Paul Dorian.   

Abstract

One of the most feared potential adverse effects of many drugs is life threatening or fatal arrhythmia--particularly torsade de pointes (TdP) ventricular tachycardia in conjunction with QT prolongation. To fully understand the implications of QT prolongation, it is essential to have an understanding of the ion currents that comprise repolarization and their relation to electrophysiological abnormalities associated with TdP. Also, the QT interval is subject to patient-specific and sometimes idiosyncratic variability. The following questions are addressed: How close is the relationship between QT prolongation and proarrhythmia? How accurately do QT-interval measurements reflect cardiac repolarization? How representative is a single QT measurement with respect to the QT response to a drug? The presumed relationship between the QT interval and myocardial repolarization will be deconstructed, demonstrating that most of the important aspects of repolarization, and subsequent arrhythmogenesis, cannot be understood only through the simple numerical measurement of the QT interval. Repolarization reserve is also discussed. Suggestions for refining the understanding of drug-induced QT prolongation, TdP, and shortcomings of some current definitions are outlined. We speculate on possible future developments in understanding this relationship.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17766320     DOI: 10.1093/europace/eum167

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  13 in total

Review 1.  Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy.

Authors:  Joanna M Brell
Journal:  Prog Cardiovasc Dis       Date:  2010 Sep-Oct       Impact factor: 8.194

Review 2.  Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.

Authors:  Vaibhav Salvi; Dilip R Karnad; Gopi Krishna Panicker; Snehal Kothari
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

Review 3.  Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.

Authors:  Arsen Uvelin; Jasmina Pejaković; Vesna Mijatović
Journal:  J Anesth       Date:  2017-02-22       Impact factor: 2.078

Review 4.  The Impact of Pazopanib on the Cardiovascular System.

Authors:  Cody N Justice; Mohamed H Derbala; Tesla M Baich; Amber N Kempton; Aaron S Guo; Thai H Ho; Sakima A Smith
Journal:  J Cardiovasc Pharmacol Ther       Date:  2018-04-29       Impact factor: 2.457

5.  QT interval instability and variability in dogs with naturally-occurring hypercortisolism.

Authors:  Beatriz de Carvalho Pato Vila; Marcela Sigolo Vanhoni; Marlos Gonçalves Sousa
Journal:  Vet Res Commun       Date:  2022-05-16       Impact factor: 2.459

6.  Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization.

Authors:  Katja E Odening; Omar Hyder; Leonard Chaves; Lorraine Schofield; Michael Brunner; Malcolm Kirk; Manfred Zehender; Xuwen Peng; Gideon Koren
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-03       Impact factor: 4.733

Review 7.  QT interval prolongation among patients treated with angiogenesis inhibitors.

Authors:  Stephane Ederhy; Ariel Cohen; Ghislaine Dufaitre; Hassan Izzedine; Christophe Massard; Catherine Meuleman; Benjamin Besse; Emmanuelle Berthelot; Franck Boccara; Jean-Charles Soria
Journal:  Target Oncol       Date:  2009-05-06       Impact factor: 4.493

Review 8.  Ventricular repolarization measures for arrhythmic risk stratification.

Authors:  Francesco Monitillo; Marta Leone; Caterina Rizzo; Andrea Passantino; Massimo Iacoviello
Journal:  World J Cardiol       Date:  2016-01-26

9.  Diurnal QT analysis in patients with sotalol after cardioversion of atrial fibrillation.

Authors:  Hanna Lenhoff; Börje Darpö; Alex Page; Jean Philippe Couderc; Per Tornvall; Mats Frick
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-02-25       Impact factor: 1.468

10.  Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.